Astellas Pharma has entered into a collaboration with Kelonia Therapeutics to create in vivo CAR T-therapies through genetic cargo delivery. This technology enables the modification of immune cells, targeting cancer cells and improving the ability to destroy tumors. The collaboration will develop up to two in vivo CAR T-therapy programs, with undisclosed targets. Kelonia will receive $40 million upfront for the first program and an additional $35 million for the second program if an option is exercised. Milestone payments could reach nearly $800 million. Kelonia also aims to make cell therapy more affordable and accessible to patients through its technology.
Source link
Astellas’s CAR Tech Deals Speed Up Its Pursuit of In Vivo Cancer Cell Therapies
